secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biofrontera Inc. (BFRI)
CIK:        0001858685
Form:       8-K
Filed at:   2026-01-13T23:59:59+00:00
Accession:  0001493152-26-001959
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biofrontera reports record preliminary Q4 2025 revenue of $17.0-17.5M, up ~35-39% YoY
--------------------------------------------------------------------------------

- Q4 2025 preliminary revenue $17.0-17.5M, highest quarterly revenue in history, YoY growth 35-39%.
- Full year 2025 preliminary revenue $41.5-42.0M, YoY growth 11-13%.
- CEO cites strong Ameluz sales execution and December pricing adjustment driving record quarter.
- Recent transaction with Biofrontera AG expected to improve gross margin profile and strengthen finances.
- Final Q4 and full year 2025 results to be reported in March 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858685/000149315226001959/0001493152-26-001959-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858685/000149315226001959/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-001959

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer